B+
Bull case
20%
Probability
Target price
$46.20
+112.1% vs current
RARE
Ultragenyx PharmaceuticalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$23.10
+6.1% vs current
B-
Bear case
20%
Probability
Target price
$11.55
-47.0% vs current
AI sentiment snapshot
Latest data as of 2026-01-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+65.8
Score
AI commentary
Investors are cautious and focused on upcoming readouts and cash-runway commentary; buying interest is contingent on binary clinical outcomes [#NEWS-2026-01-05]. Corporate messaging stresses program prioritization and cost discipline, which tempers but does not eliminate upside expectations pending milestones [#PR-2025-11-01].
RankAlpha Sentiment AI - 2026-01-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-06catalystNext quarterly financial report (10-Q) / corporate updateMedium impact
Quarterly results updating cash runway and program timelines; date set to the next filing window [#10Q-Est].
2026-09-30eventPhase readout for late-stage program (window end)High impact
Pivotal readout for a lead program; date uses a window-end assumption due to no public schedule [#PR-WindowAssumption].
2027-01-06catalystRegulatory milestone / early commercial uptakeHigh impact
Regulatory filing/decision or early commercial metrics that would materially alter revenue trajectory; conservative one-year horizon [#CorpPlan-Est].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-06 • Updated nightlySource: Internal modelMethodology